Market Research Logo

Pneumonia Drug Development Pipeline Review, 2017

Pneumonia Drug Development Pipeline Review, 2017

Summary

Community acquired pneumonia refers to pneumonia contracted by a person who has had little contact with the healthcare system. There are a total of 20 products in development for this indication, by 17 companies. Key companies operating in this pipeline space include TaiGen Biotechnology and Merck.

Hospital acquired pneumonia refers to any pneumonia contracted by a patient in a hospital at least 48-72 hours after being admitted, usually caused by a bacterial infection. There are a total of 39 products in development for this indication, by 29 companies. Key companies operating in this pipeline space include Aridis Pharmaceuticals, Wockhardt, AstraZeneca and Merck.

Finally, Ventilator-associated pneumonia is characterized by age-related hyperplasia of the prostate gland (with or without glandular enlargement), lower urinary tract symptoms and bladder flow obstruction. There are a total of 34 products in development for this indication, by 27 companies. Key companies operating in this pipeline space include Aridis Pharmaceuticals, AstraZeneca, Merck and Polyphor.

The most common targets within community acquired pneumonia are DNA gyrase, DNA topoisomerase and ribosomal RNA, common targets of antibiotics. Hospital acquired and ventilator associated pneumonia share many of the same targets and are most frequently targeted towards beta lactamase and ribosomal RNA, also common targets of antibiotic treatments and closely reflecting the current treatment landscape of these diseases.

The report,Pneumonia Drug Development Pipeline Review, 2017 provides an overview of the pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Community Acquired Pneumonia, Hospital Acquired Pneumonia and Ventilator Associated Pneumonia and features dormant and discontinued projects.

Scope

  • Which companies are the most active within the pipeline for pneumonia therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of pneumonia?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Pneumonia Report Coverage
    • Community Acquired Pneumonia – Overview
    • Hospital Acquired Pneumonia (HAP) –Overview
    • Ventilator Associated Pneumonia (VAP) –Overview
  • Therapeutics Development
    • Community Acquired Pneumonia
      • Pipeline Overview
        • Table Figure 1: Number of Products under Development for Community Acquired Pneumonia
        • Table Number of Products under Development for Community Acquired Pneumonia
      • Pipeline by Companies
        • Table Figure 2: Number of Products under Development by Companies Community Acquired Pneumonia
        • Table Number of Products under Development by Companies Community Acquired Pneumonia
      • Products under Development by Companies
        • Table Products under Development by Companies Community Acquired Pneumonia
    • Hospital Acquired Pneumonia (HAP)
      • Pipeline Overview
        • Table Figure 3: Number of Products under Development for Hospital Acquired Pneumonia (HAP)
        • Table Number of Products under Development for Hospital Acquired Pneumonia (HAP)
      • Pipeline by Companies
        • Table Figure 4: Number of Products under Development by Companies Hospital Acquired Pneumonia (HAP)
        • Table Number of Products under Development by Companies Hospital Acquired Pneumonia (HAP)
      • Products under Development by Companies
        • Table Products under Development by Companies Hospital Acquired Pneumonia (HAP)
    • Ventilator Associated Pneumonia (VAP)
      • Pipeline Overview
        • Table Figure 5: Number of Products under Development for Ventilator Associated Pneumonia (VAP)
        • Table Number of Products under Development for Ventilator Associated Pneumonia (VAP)
      • Pipeline by Companies
        • Table Figure 6: Number of Products under Development by Companies Ventilator Associated Pneumonia (VAP)
        • Table Number of Products under Development by Companies Ventilator Associated Pneumonia (VAP)
      • Products under Development by Companies
        • Table Products under Development by Companies Ventilator Associated Pneumonia (VAP)
  • Therapeutics Assessment
    • Community Acquired Pneumonia
      • Assessment by Target
        • Table Figure 7: Number of Products by Targets Community Acquired Pneumonia
        • Table Figure 8: Number of Products by Stage and Targets Community Acquired Pneumonia
        • Table Number of Products by Stage and Target Community Acquired Pneumonia
      • Assessment by Mechanism of Action
        • Table Figure 9: Number of Products by Mechanism of Actions Community Acquired Pneumonia
        • Table Figure 10: Number of Products by Stage and Top 10 Mechanism of Actions Community Acquired Pneumonia
        • Table Number of Products by Stage and Mechanism of Action Community Acquired Pneumonia
      • Assessment by Route of Administration
        • Table Figure 11: Number of Products by Routes of Administration Community Acquired Pneumonia
        • Table Figure 12: Number of Products by Stage and Routes of Administration Community Acquired Pneumonia
        • Table Number of Products by Stage and Route of Administration Community Acquired Pneumonia
      • Assessment by Molecule Type
        • Table Figure 13: Number of Products by Molecule Types Community Acquired Pneumonia
        • Table Figure 14: Number of Products by Stage and Molecule Types Community Acquired Pneumonia
        • Table Number of Products by Stage and Molecule Type Community Acquired Pneumonia
    • Hospital Acquired Pneumonia (HAP)
      • Assessment by Target
        • Table Figure 15: Number of Products by Top 10 Targets Hospital Acquired Pneumonia (HAP)
        • Table Figure 16: Number of Products by Stage and Top 10 Targets Hospital Acquired Pneumonia (HAP)
        • Table Number of Products by Stage and Target Hospital Acquired Pneumonia (HAP)
      • Assessment by Mechanism of Action
        • Table Figure 17: Number of Products by Top 10 Mechanism of Actions Hospital Acquired Pneumonia (HAP)
        • Table Figure 18: Number of Products by Stage and Top 10 Mechanism of Actions Hospital Acquired Pneumonia (HAP)
        • Table Number of Products by Stage and Mechanism of Action Hospital Acquired Pneumonia (HAP)
      • Assessment by Route of Administration
        • Table Figure 19: Number of Products by Routes of Administration Hospital Acquired Pneumonia (HAP)
        • Table Figure 20: Number of Products by Stage and Routes of Administration Hospital Acquired Pneumonia (HAP)
        • Table Number of Products by Stage and Route of Administration Hospital Acquired Pneumonia (HAP)
      • Assessment by Molecule Type
        • Table Figure 21: Number of Products by Molecule Types Hospital Acquired Pneumonia (HAP)
        • Table Figure 22: Number of Products by Stage and Molecule Types Hospital Acquired Pneumonia (HAP)
        • Table Number of Products by Stage and Molecule Type Hospital Acquired Pneumonia (HAP)
    • Ventilator Associated Pneumonia (VAP)
      • Assessment by Target
        • Table Figure 23: Number of Products by Top 10 Targets Ventilator Associated Pneumonia (VAP)
        • Table Figure 24: Number of Products by Stage and Top 10 Targets Ventilator Associated Pneumonia (VAP)
        • Table Number of Products by Stage and Target Ventilator Associated Pneumonia (VAP)
      • Assessment by Mechanism of Action
        • Table Figure 25: Number of Products by Top 10 Mechanism of Actions Ventilator Associated Pneumonia (VAP)
        • Table Figure 26: Number of Products by Stage and Top 10 Mechanism of Actions Ventilator Associated Pneumonia (VAP)
        • Table Number of Products by Stage and Mechanism of Action Ventilator Associated Pneumonia (VAP)
      • Assessment by Route of Administration
        • Table Figure 27: Number of Products by Top 10 Routes of Administration Ventilator Associated Pneumonia (VAP)
        • Table Figure 28: Number of Products by Stage and Top 10 Routes of Administration Ventilator Associated Pneumonia (VAP)
        • Table Number of Products by Stage and Route of Administration Ventilator Associated Pneumonia (VAP)
      • Assessment by Molecule Type
        • Table Figure 29: Number of Products by Molecule Types Ventilator Associated Pneumonia (VAP)
        • Table Figure 30: Number of Products by Stage and Molecule Types Ventilator Associated Pneumonia (VAP)
        • Table Number of Products by Stage and Molecule Type Ventilator Associated Pneumonia (VAP)
  • Companies Involved in Therapeutics Development
    • Community Acquired Pneumonia
      • Aridis Pharmaceuticals LLC
        • Table Community Acquired Pneumonia – Pipeline by Aridis Pharmaceuticals LLC
      • Biotest AG
        • Table Community Acquired Pneumonia – Pipeline by Biotest AG
      • InflaRx GmbH
        • Table Community Acquired Pneumonia – Pipeline by InflaRx GmbH
      • ioGenetics Inc
        • Table Community Acquired Pneumonia – Pipeline by ioGenetics Inc
      • Kyorin Pharmaceutical Co Ltd
        • Table Community Acquired Pneumonia – Pipeline by Kyorin Pharmaceutical Co Ltd
      • Melinta Therapeutics Inc
        • Table Community Acquired Pneumonia – Pipeline by Melinta Therapeutics Inc
      • Merck & Co Inc
        • Table Community Acquired Pneumonia – Pipeline by Merck & Co Inc
      • Nabriva Therapeutics AG
        • Table Community Acquired Pneumonia – Pipeline by Nabriva Therapeutics AG
      • Paratek Pharmaceuticals Inc
        • Table Community Acquired Pneumonia – Pipeline by Paratek Pharmaceuticals Inc
      • TaiGen Biotechnology Co Ltd
        • Table Community Acquired Pneumonia – Pipeline by TaiGen Biotechnology Co Ltd
      • Takeda Pharmaceutical Company Ltd
        • Table Community Acquired Pneumonia – Pipeline by Takeda Pharmaceutical Company Ltd
      • Tetraphase Pharmaceuticals Inc
        • Table Community Acquired Pneumonia – Pipeline by Tetraphase Pharmaceuticals Inc
      • TiGenix NV
        • Table Community Acquired Pneumonia – Pipeline by TiGenix NV
      • Wockhardt Ltd
        • Table Community Acquired Pneumonia – Pipeline by Wockhardt Ltd
    • Hospital Acquired Pneumonia (HAP)
      • Achaogen Inc
        • Table Hospital Acquired Pneumonia (HAP) –Pipeline by Achaogen Inc
      • Adenium Biotech ApS
        • Table Hospital Acquired Pneumonia (HAP) –Pipeline by Adenium Biotech ApS
      • Aridis Pharmaceuticals LLC
        • Table Hospital Acquired Pneumonia (HAP) –Pipeline by Aridis Pharmaceuticals LLC
      • AstraZeneca Plc
        • Table Hospital Acquired Pneumonia (HAP) –Pipeline by AstraZeneca Plc
      • Bayer AG
        • Table Hospital Acquired Pneumonia (HAP) –Pipeline by Bayer AG
      • Cardeas Pharma Corp
        • Table Hospital Acquired Pneumonia (HAP) –Pipeline by Cardeas Pharma Corp
      • Destiny Pharma Ltd
        • Table Hospital Acquired Pneumonia (HAP) –Pipeline by Destiny Pharma Ltd
      • Dong-A Socio Holdings Co Ltd
        • Table Hospital Acquired Pneumonia (HAP) –Pipeline by Dong-A Socio Holdings Co Ltd
      • Lakewood-Amedex Inc
        • Table Hospital Acquired Pneumonia (HAP) –Pipeline by Lakewood-Amedex Inc
      • MedImmune LLC
        • Table Hospital Acquired Pneumonia (HAP) –Pipeline by MedImmune LLC
      • Meiji Seika Pharma Co Ltd
        • Table Hospital Acquired Pneumonia (HAP) –Pipeline by Meiji Seika Pharma Co Ltd
      • Melinta Therapeutics Inc
        • Table Hospital Acquired Pneumonia (HAP) –Pipeline by Melinta Therapeutics Inc
      • Merck & Co Inc
        • Table Hospital Acquired Pneumonia (HAP) –Pipeline by Merck & Co Inc
      • Motif Bio Plc
        • Table Hospital Acquired Pneumonia (HAP) –Pipeline by Motif Bio Plc
      • Nabriva Therapeutics AG
        • Table Hospital Acquired Pneumonia (HAP) –Pipeline by Nabriva Therapeutics AG
      • Polyphor Ltd
        • Table Hospital Acquired Pneumonia (HAP) –Pipeline by Polyphor Ltd
      • Sealife PHARMA GMBH
        • Table Hospital Acquired Pneumonia (HAP) –Pipeline by Sealife PHARMA GMBH
      • Shionogi & Co Ltd
        • Table Hospital Acquired Pneumonia (HAP) –Pipeline by Shionogi & Co Ltd
      • Tetraphase Pharmaceuticals Inc
        • Table Hospital Acquired Pneumonia (HAP) –Pipeline by Tetraphase Pharmaceuticals Inc
      • The Medicines Company
        • Table Hospital Acquired Pneumonia (HAP) –Pipeline by The Medicines Company
      • Theravance Biopharma Inc
        • Table Hospital Acquired Pneumonia (HAP) –Pipeline by Theravance Biopharma Inc
      • Wockhardt Ltd
        • Table Hospital Acquired Pneumonia (HAP) –Pipeline by Wockhardt Ltd
      • Zavante Therapeutics Inc
        • Table Hospital Acquired Pneumonia (HAP) –Pipeline by Zavante Therapeutics Inc
    • Ventilator Associated Pneumonia (VAP)
      • Achaogen Inc
        • Table Ventilator Associated Pneumonia (VAP) –Pipeline by Achaogen Inc
      • Adenium Biotech ApS
        • Table Ventilator Associated Pneumonia (VAP) –Pipeline by Adenium Biotech ApS
      • Aridis Pharmaceuticals LLC
        • Table Ventilator Associated Pneumonia (VAP) –Pipeline by Aridis Pharmaceuticals LLC
      • AstraZeneca Plc
        • Table Ventilator Associated Pneumonia (VAP) –Pipeline by AstraZeneca Plc
      • Bayer AG
        • Table Ventilator Associated Pneumonia (VAP) –Pipeline by Bayer AG
      • Cardeas Pharma Corp
        • Table Ventilator Associated Pneumonia (VAP) –Pipeline by Cardeas Pharma Corp
      • Destiny Pharma Ltd
        • Table Ventilator Associated Pneumonia (VAP) –Pipeline by Destiny Pharma Ltd
      • Dong-A Socio Holdings Co Ltd
        • Table Ventilator Associated Pneumonia (VAP) –Pipeline by Dong-A Socio Holdings Co Ltd
      • Lakewood-Amedex Inc
        • Table Ventilator Associated Pneumonia (VAP) –Pipeline by Lakewood-Amedex Inc
      • MedImmune LLC
        • Table Ventilator Associated Pneumonia (VAP) –Pipeline by MedImmune LLC
      • Meiji Seika Pharma Co Ltd
        • Table Ventilator Associated Pneumonia (VAP) –Pipeline by Meiji Seika Pharma Co Ltd
      • Merck & Co Inc
        • Table Ventilator Associated Pneumonia (VAP) –Pipeline by Merck & Co Inc
      • Motif Bio Plc
        • Table Ventilator Associated Pneumonia (VAP) –Pipeline by Motif Bio Plc
      • Nabriva Therapeutics AG
        • Table Ventilator Associated Pneumonia (VAP) –Pipeline by Nabriva Therapeutics AG
      • Polyphor Ltd
        • Table Ventilator Associated Pneumonia (VAP) –Pipeline by Polyphor Ltd
      • Shionogi & Co Ltd
        • Table Ventilator Associated Pneumonia (VAP) –Pipeline by Shionogi & Co Ltd
      • Tetraphase Pharmaceuticals Inc
        • Table Ventilator Associated Pneumonia (VAP) –Pipeline by Tetraphase Pharmaceuticals Inc
      • The Medicines Company
        • Table Ventilator Associated Pneumonia (VAP) –Pipeline by The Medicines Company
      • Theravance Biopharma Inc
        • Table Ventilator Associated Pneumonia (VAP) –Pipeline by Theravance Biopharma Inc
      • Wockhardt Ltd
        • Table Ventilator Associated Pneumonia (VAP) –Pipeline by Wockhardt Ltd
      • Zavante Therapeutics Inc
        • Table Ventilator Associated Pneumonia (VAP) –Pipeline by Zavante Therapeutics Inc
  • Dormant Projects
    • Community Acquired Pneumonia
      • Table Community Acquired Pneumonia – Dormant Projects
    • Hospital Acquired Pneumonia (HAP)
      • Table Hospital Acquired Pneumonia (HAP) –Dormant Projects
    • Ventilator Associated Pneumonia (VAP)
      • Table Ventilator Associated Pneumonia (VAP) –Dormant Projects
  • Discontinued Products
    • Community Acquired Pneumonia
      • Table Community Acquired Pneumonia – Discontinued Products
    • Hospital Acquired Pneumonia (HAP)
      • Table Hospital Acquired Pneumonia (HAP) –Discontinued Products
    • Ventilator Associated Pneumonia (VAP)
      • Table Ventilator Associated Pneumonia (VAP) –Discontinued Products
  • Product Development Milestones
    • Community Acquired Pneumonia
      • Featured News & Press Releases
    • Hospital Acquired Pneumonia (HAP)
      • Featured News & Press Releases
    • Ventilator Associated Pneumonia (VAP)
      • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report